Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786210 · ClinicalTrials.gov registry record · Phase 4
Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid
A Phase 4 study of Keloid Scar, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04786210 is a Phase 4 study of Keloid Scar that has completed, run by NYU Langone Health. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04786210, a Phase 4 study of Keloid Scar, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a split-scar study with a target sample size of 20. There are two interventions: fractional erbium:YAG-assisted drug delivery of 5-fluorouracil and fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide. Patients will undergo treatments in a series of 4 treatments at approximately 4 week ± 1 week intervals. Investigators will monitor for safety and continued benefit after the end of the interventional treatment.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil
- COMBINATION_PRODUCT Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-01-30 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04786210
The ClinicalTrials.gov registry entry for NCT04786210 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keloid Scar appearing as the primary indexed condition, and to 2 interventions - of which Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil is the first listed.
NCT04786210 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04786210 about?
NCT04786210 is a clinical study titled "Treatment of Keloids With Fractional Erbium Laser-Assisted 5-Fluorouracil Versus Laser-Assisted Corticosteroid". This is a split-scar study with a target sample size of 20. There are two interventions: fractional erbium:YAG-assisted drug delivery of 5-fluorouracil and fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide. Patients will undergo treatments in a series of 4 treatments at approxi...
What is the current status of trial NCT04786210?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2021-01-30. Estimated completion is 2022-12-16.
What conditions does trial NCT04786210 study?
This clinical trial studies the following conditions: Keloid Scar.
What interventions are being tested in trial NCT04786210?
The interventions under investigation include: Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil (COMBINATION_PRODUCT), Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04786210?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04786210 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.